Publication | Closed Access

A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma

OncologyEsophageal CancerGastrointestinal OncologyMedicinePathologyUntreated PatientsPharmacotherapyMetastatic GastricCancer TreatmentPharmacologyRadiation Oncology2-H Intravenous Infusion